Cholinesterase inhibitors, and particularly donepezil, are the standard of care in the management of Alzheimer’s disease. Newer agents, such as rivastigmine, galantamine, and metrifonate, provide therapeutic alternatives but have advantages and disadvantages compared with donepezil. Clinical studies and continued research of the pathophysiology of Alzheimer’s disease help define the role of both the newer agents and the original cholinesterase inhibitor, tacrine. Therapies with other mechanisms of action, such as estrogen and nonsteroidal anti-inflammatory drugs (NSAIDs), are also being actively investigated for their effects on cognition. Since 1993, 8 new antiepileptic drugs have been approved by the FDA, including felbamate, gabapentin, lamotrigine, topiramate, tiagabine, and 3 recently introduced agents, oxcarbazepine, levetiracetam, and zonisamide. These second-generation agents are generally more tolerable and have fewer drug interactions than traditional antiepileptics, and some provide alternative mechanisms that may be beneficial in the management of refractory epileptic disorders. However, until clinical experience with the newer antiepileptics accumulates and well-designed comparative trials are conducted, a review of individual studies of the safety and efficacy of the newer agents helps provide the basis for treatment decisions. New information regarding traditional therapies, including new formulations and updated treatment guidelines, also assist clinicians in optimizing antiepileptic therapy.
Donnan GA, Davis SM. Neurology: reflections on the past millennium as we enter the next. J Clin Neurosci. 2000;7(1):1-2.
2.
Pharmaceutical Manufacturer’s Association. PhRMA Pharmaceutical Industry Profile, 2000. Available at: http://www.phrma.org/publications/publications/profile00/toc.phtml. Accessed March 15, 2001.
3.
Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer’s disease and related disorders. JAMA. 1997;278: 1363-1371.
Crismon ML, Eggert AE. “Alzheimer’s disease.” In Dipiro JT, Talbert RL, Yee GC, et al. Pharmacother: A Pathophysiological Approach. 4th ed.Stamford, Conn: Appleton and Lange; 1999.
6.
Krall WJ, Sramek JJ, Cutler NR. Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease. Ann Pharmacother. 1999;33(4):441-450.
7.
Oken BS, Storzbach DM, Kaye JA. The efficacy of ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurology. 1998;55(11):1409-1415.
8.
Jann MW. Pharmacology and clinical efficacy of cholinesterase inhibitors. AJHP. 1998;55(suppl 2):s22-s25.
9.
Williams BR. Metrifonate: a new agent for the treatment of Alzheimer’s disease. AJHP. 1999;56(5):427-432.
10.
Qizilbash N, Whitehead A, Higgins J, et al. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. JAMA. 1998;280(20):1777-1782.
11.
Farlow MR, Lahiri DK, Poirier J, et al. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer’s disease. Neurology. 1998;50(3):669-677.
12.
Aricept®(donepezil hydrochloride) tablets [package insert]. New York: Roerig Division of Pfizer; February 2000.
13.
Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med. 1998;158(9):1021-1031.
14.
Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology. 1998;50(1):136-145.
15.
Simonson W.Promising agents for treating Alzheimer’s disease. AJHP. 1998;55(suppl 2):s11-s16.
16.
Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol. 1998;8(1):67-75.
17.
Greenberg SM, Tennis MK, Brown LB, et al. Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurology. 2000;57(1):94-99.
18.
Jann MW. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer’s disease. Pharmacother. 2000;20(1):1-12.
19.
Exelon® (rivastigmine tartrate) capsules [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; January 2001.
20.
Corey-Bloom J, Anand R, Veach J.A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol. 1998;1:55-65.
21.
Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ. 1999;318:633-638.
22.
Forette F, Anand R, Gharabawi G.A phase II study in patients with Alzheimer’s disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). Eur J Neurology. 1999;6(4):423-429.
23.
Jann MW, Cyrus PA, Eisner LS, et al. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer’s disease: a randomized, double-masked, placebo-controlled trial. Clin Ther. 1999;21(1):88-102.
24.
Becker RE, Colliver JA, Markwell SJ, et al. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease. Alzheimer Dis Assoc Disord. 1996;10(2):124-131.
25.
Pettigrew LC, Bieber F, Lettieri J, et al. Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer’s disease. J Clin Pharmacol. 1998;38(3):236-245.
Cummings JL, Cyrus PA, Bieber F, et al. Metrifonate treatment of the cognitive deficits of Alzheimer’s disease. Neurology. 1998;50(5):1214-1221.
28.
Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer’s disease. Neurology. 1998;50(5):1222-1230.
29.
Farlow MR, Cyrus PA, Nadel A, et al. Metrifonate treatment of AD: influence of APOE genotype. Neurology. 1999;53(9):2010-2016.
30.
Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000;54(12):2261-2268.
31.
Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology. 2000;54:2269-2276.
32.
Yaffe K, Sawaya G, Lieberburg I, et al. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA. 1998;279(9):688-695.
33.
Honjo H, Ogino Y, Naitoh K, et al. An effect of conjugated estrogen to cognitive impairment in women with senile dementia-Alzheimer’s type: a placebo-controlled, double blind study. J Jpn Menopause Soc. 1993;1:167-171.
34.
Baldereschi M, Di Carlo A, Lepore V, et al. Estrogen-replacement therapy and Alzheimer’s disease in the Italian Longitudinal Study on Aging. Neurology. 1998;50(4):996-1002.
35.
Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer’s disease in women: randomized, double-blind, placebo-controlled trial. Neurology. 2000;54(2):295-301.
36.
Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. JAMA. 2000;283(8):1007-1015.
37.
Flynn BL, Theesen, KA. Pharmacologic management of Alzheimer disease, Part III: nonsteroidal anti-inflammatory drugs—emerging protective evidence?Ann Pharmacother. 1999;33: 840-849.
38.
Karplus TM, Saag KG. Nonsteroidal anti-inflammatory drugs and cognitive function. Do they have a beneficial or deleterious effect?Drug Safety. 1998;19(6):427-433.
39.
McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factor in Alzheimer’s disease: a review of 17 epidemiologic studies. Neurology. 1996;47:425-432.
40.
Stewart WF, Kawas C, Corrada M, et al. Risk of Alzheimer’s disease and duration of NSAID use. Neurology. 1997;48:626-632.
41.
Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer’s disease. Neurology. 1993;43:1609-1611.
42.
Scharf S, Mander A, Ugoni A, et al. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease. Neurology. 1999;53:197-201.
43.
National Institute on Aging. Alzheimer’s disease anti-inflammatory prevention trial (ADAPT). Available at: www.clinicaltrials.gov. Accessed March 26, 2001.
Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures. Results of a double-blind, randomized clinical trial. Neurology. 2000;55:236-242.
46.
Betts T, Waegemans T, Crawford P.A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure. 2000;9:80-87.
Beydoun A.Safety and efficacy of oxcarbazepine: results of randomized, double-blind trials. Pharmacother. 2000;20(8, pt 2):152S-158S.
49.
Lott RS, Helmboldt K.Oxcarbazepine: a carbamazepine analogue for partial seizures in adults and children with epilepsy. Formulary. 2000;35:219-233.
50.
Trileptal® (oxcarbazepine) tablets [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; May 2001.
51.
Beydoun A, Sachdeo RC, Rosenfeld, WE, et al. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial. Neurology. 2000;54:2245-2251.
52.
Schachter SC, Vazquez B, Fisher RS, et al. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology. 1999;52:732-737.
53.
Mimaki, T.Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther Drug Monitoring. 1998;20(6):593-597.
54.
Oommen KJ, Mathews S.Zonisamide: a new antiepileptic drug. Clin Neuropharmacol. 1999;22(4):192-200.
French JA. Vigabatrin. Epilepsia. 1999;40(suppl 5):S11-S16.
59.
Hardus P, Verduin WM, Postma G, et al. Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication. Epilepsia. 2000;41(5):581-587.
60.
Manuchehri K, Goodman S, Siviter L, et al. A controlled study of vigabatrin and visual abnormalities. Br J Ophthalmol. 2000; 84(5):499-505.
61.
Nousiainen I, Kalvainen R, Mantyjarvi M.Color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy. Ophthalmology. 2000;107(5):884-888.
62.
Abbott Laboratories. Dear health care professional: important drug warning. Available at http://www.fda.gov/medwatch/safety/2000/depako.htm. Accessed July 2000.
63.
Food and Drug Administration, Center for Drug Evaluation and Research. New and Generic Drug Approvals 1998-2000. Available at http://www.fda.gov/cder/approval. Accessed August 18,2000.
64.
Naritoku DK, Mueed S.Intravenous loading of valproate in epilepsy. Clin Neuropharmacol. 1999;22(2):102-106.
65.
Meek PD, Davis SN, Collins DM, et al. Guidelines for nonemergency use of parenteral phenytoin products: proceedings of an expert panel consensus process. Arch Intern Med. 1999;159(22):2639-2644.
66.
Rzany, B, Correia, O, Kelly, JP, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: case-control study. Lancet. 1999;353:2190-2194.
67.
Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology. 1999;52:1330-1337.
68.
Reife R, Pledger G, Wu SC. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia. 2000; 41(suppl 1):S66-S71.
69.
French J, Smith M, Faught E, et al. Practice advisory: the use of felbamate in the treatment of patients with intractable epilepsy. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 1999;40(6):803-808.
70.
Datta PK, Crawford PM. Refractory epilepsy: treatment with new antiepileptic drugs. Seizure. 2000;9(1):51-57.
71.
Anonymous. Consensus statements: medical management of epilepsy. Neurology. 1998;51(5 suppl 4):S39-S43.
72.
Mattson RH. Medical management of epilepsy in adults. Neurology. 1998;51(suppl 4):S15-S20.
73.
Quality Standards Committee of the American Academy of Neurology. Practice parameter: management issues for women with epilepsy (Summary statement). Neurology. 1998;51:944-948.
